Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

angelini pharma Česká republika s.r.o., brno array - 11589 trazodon-hydrochlorid - tableta s prodlouženým uvolňováním - 150mg - trazodon

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

angelini pharma Česká republika s.r.o., brno array - 11589 trazodon-hydrochlorid - tableta s prodlouženým uvolňováním - 300mg - trazodon

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 1876 vankomycin-hydrochlorid - prášek pro infuzní roztok - 1000mg - vankomycin

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 1876 vankomycin-hydrochlorid - prášek pro infuzní roztok - 500mg - vankomycin

Euroopan unioni - tšekki - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatetické novotvary - diagnostické radiofarmaka - tento léčivý přípravek je určen pouze pro diagnostické účely. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Euroopan unioni - tšekki - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.